SEARCH

SEARCH BY CITATION

References

  • Abdallah, A., Coghlan, D.W., Duncan, E.M., Chunilal, S.D. & Lloyd, J.V. (2005) Rituximab-induced long-term remission in patients with refractory acquired hemophilia. Journal of Thrombosis and Haemostasis, 3, 25892590.
  • Aggarwal, A., Grewal, R., Green, R.J., Boggio, L., Green, D., Weksler, B.B., Wiestner, A. & Schechter, G.P. (2005) Rituximab for autoimmune haemophilia: a proposed treatment algorithm. Haemophilia, 11, 1319.
  • Ahmad, A., Aggarwal, A., Sharma, D., Dave, H.P., Kinsella, V., Rick, M.E. & Schechter, G.P. (2004) Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP). American Journal of Hematology, 77, 171176.
  • Aksoy, S., Harputluoglu, H., Kilickap, S., Dede, D.S., Dizdar, O., Altundag, K. & Barista, I. (2007) Rituximab-related viral infections in lymphoma patients. Leukemia and Lymphoma, 48, 13071312.
  • Alvarado, Y., Yao, X., Jumper, C., Hardwicke, F., D’Cunha, N. & Cobos, E. (2007) Acquired hemophilia: a case report of 2 patients with acquired factor VIII inhibitor treated with rituximab plus a short course of steroid and review of the literature. Clinical and Applied Thrombosis/Hemostasis, 13, 443448.
  • Arnold, D.M., Dentali, F., Crowther, M., Meyer, R., Cook, R., Sigouin, C., Fraser, G., Lim, W. & Kelton, J. (2007) Systemic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Annals of Internal Medicine, 146, 2533.
  • Aronis, S., Platokouki, H., Avgeri, M., Pergantou, H. & Keramidas, D. (2004) Retrospective evaluation of long-term efficacy and safety of splenectomy in chronic idiopathic thrombocytopenic purpura in children. Acta Paediatrica, 93, 638642.
  • Benetatos, L., Vassou, A. & Bourantas, K.L. (2006) Effectiveness of rituximab as prophylaxis in thrombotic thrombocytopenic purpura. Clinical and Laboratory Haematology, 28, 288289.
  • Bennett, C.M., Rogers, Z.R., Kinnamon, D.D., Bussel, J.B., Mahoney, D.H., Abshire, T.C., Sawaf, H., Moore, T.B., Loh, M.L., Glader, B.E., McCarthy, M.C., Mueller, B.U., Olson, T.A., Lorenzana, A.N., Mentzer, W.C., Buchanan, G.R., Feldman, H.A. & Neufeld, E.J. (2006) Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood, 107, 26392642.
  • Berentsen, S., Ulvestad, E., Gjertsen, B.T., Hjorth-Hansen, H., Langholm, R., Knutsen, H., Ghanima, W., Shammas, F.V. & Tjønnfjord, G.E. (2004) Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood, 103, 29252928.
  • Berentsen, S., Ulvestad, E., Langholm, R., Beiske, K., Hjorth-Hansen, H., Ghanima, W., Sørbø, J.H. & Tjønnfjord, G.E. (2006) Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica, 91, 460466.
  • Berezné, A., Stieltjes, N., Le-Guern, V., Teixeira, L., Billy, C., Roussel-Robert, V., Flaujac, C., Horellou, M.H., Guillevin, L. & Mouthon, L. (2006) Rituximab alone or in association with corticosteroids in the treatment of acquired factor VIII inhibitors: report of two cases. Transfusion Medicine, 16, 209212.
  • Bisharat, N., Omari, H., Lavi, I. & Raz, R. (2001) Risk of infection and death among post-splenectomy patients. Journal of Infection, 43, 182186.
  • Blanchette, V.S. & Price, V. (2003) Childhood chronic immune thrombocytopenic purpura: unresolved issues. Journal of Pediatric Hematology/Oncology, 25(Suppl. 1), S28S33.
  • Boctor, F.N. & Smith, J.A. (2006) Timing of plasma exchange and rituximab for the treatment of thrombotic thrombocytopenic purpura. American Journal of Clinical Pathology, 126, 965.
  • Boggio, L.N. & Green, D. (2001) Acquired hemophilia. Reviews in Clinical and Experimental Hematology, 5, 389404.
  • Bolton-Maggs, P.H. (2000) Idiopathic thrombocytopenic purpura. Archives of Disease in Childhood, 83, 220222.
  • Boumpas, D.T., Chrousos, G.P., Wilder, R.L., Cupps, T.R. & Balow, J.E. (1993) Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Annals of Internal Medicine, 119, 11981208.
  • Braendstrup, P., Bjerrum, O.W., Nielsen, O.J., Jensen, B.A., Clausen, N.T., Hansen, P.B., Andersen, I., Schmidt, K., Andersen, T.M., Peterslund, N.A., Birgens, H.S., Plesner, T., Pedersen, B.B. & Hasselbalch, H.C. (2005) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. American Journal of Hematology, 78, 275280.
  • Brunskill, S.J., Tusold, A., Benjamin, S., Stanworth, S.J. & Murphy, M.F. (2007) A systematic review of randomized controlled trials for plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Transfusion Medicine (Oxford, England), 17, 1735.
  • Carter, R.H. (2004) B cells in health and disease. Mayo Clinic Proceedings, 81, 377384.
  • Chemnitz, J., Draube, A., Scheid, C., Staib, P., Schulz, A., Diehl, V. & Söhngen, D. (2002) Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. American Journal of Hematology, 71, 105108.
  • Chow, K.V., Carroll, R., Branley, P., Nicholls, K., Becker, G. & Hogan, C. (2007) Anti-CD20 antibody in thrombotic thrombocytopenic purpura refractory to plasma exchange. Internal Medicine Journal, 37, 329332.
  • Cines, D.B. & Blanchette, V.S. (2002) Immune thrombocytopenic purpura. New England Journal of Medicine, 346, 9951008.
  • Cines, D.B. & Bussel, J.B. (2005) How I treat idiopathic thrombocytopenic purpura (ITP). Blood, 106, 22442251.
  • Clatworthy, M.R. & Jayne, D.R. (2006) Acquired hemophilia in association with ANCA-associated vasculitis: response to rituximab. American Journal of Kidney Diseases, 47, 680682.
  • Cohen, S.B. (2005) B-cell depletion for rheumatic diseases: where are we? MedGenMed: Mediscape General Medicine, 7, 72.
  • Cohen, S.B., Emery, P., Greenwald, M.W., Dougados, M., Furie, R.A., Genovese, M.C., Keystone, E.C., Loveless, J.E., Burmester, G.R., Cravets, M.W., Hessey, E.W., Shaw, T., Totoritis, M.C. & the REFLEX Trial Group (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis and Rheumatism, 54, 27932806.
  • Collins, P., Baglin, T., Brown, S., Dolan, G., Hanley, J., Keeling, D., Liesner, R., Makris, M., Hay, C. & on Behalf of UKHCDO9 (2005) UKHCDO Acquired Haemophilia Study: a complete national cohort. Blood, 106, 98a (Abstract 322).
  • Coopamah, M., Garvey, M.B., Freedman, J. & Semple, J.W. (2003) Cellular immune mechanisms in autoimmune thrombocytopenic purpura: an update. Transfusion Medicine Reviews, 17, 6980.
  • Cooper, N., Stasi, R., Cunningham-Rundles, S., Feuerstein, M.A., Leonard, J.P., Amadori, S. & Bussel, J.B. (2004) The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. British Journal of Haematology, 125, 232239.
  • Cooper, N., Evangelista, M.L., Amadori, S. & Stasi, R. (2007) Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura? Current Opinion in Hematology, 14, 642646.
  • Cvetkovic, R.S. & Perry, C.M. (2006) Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs, 66, 791820.
  • D’Arena, G., Laurenti, L., Capalbo, S., D’Arco, A.M., De Filippi, R., Marcacci, G., Di Renzo, N., Storti, S., Califano, C., Vigliotti, M.L., Tarnani, M., Ferrara, F. & Pinto, A. (2006) Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. American Journal of Hematology, 81, 598602.
  • D’Arena, G., Califano, C., Annunziata, M., Tartarone, A., Capalbo, S., Villani, O., Amendola, G., Pietrantuono, G., Ferrara, F., Pinto, A., Musto, P., D’Arco, A.M. & Cascavilla, N. (2007) Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients. European Journal of Haematology, 79, 5358.
  • Darabi, K. & Berg, A.H. (2006) Rituximab can be combined with daily plasma exchange to achieve effective B-cell depletion and clinical improvement in acute autoimmune TTP. American Journal of Clinical Pathology, 125, 592597.
  • Delgado, J., Jimenez-Yuste, V., Hernandez-Navarro, F. & Villar, A. (2003) Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. British Journal of Haematology, 121, 2135.
  • Edwards, J.C., Szczepanski, L., Szechinski, J., Filipowicz-Sosnowska, A., Emery, P., Close, D.R., Stevens, R.M. & Shaw, T. (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. New England Journal of Medicine, 350, 25722581.
  • El-Najjar, I., Rule, S.A.J. & Nokes, T.J.C. (2006) A fixed, low dose of anti-CD20 antibody (Rituximab) is an effective treatment for patients with chronic immune thrombocytopenia. British Journal of Haematology, 133(Suppl. 1), 79 (Abstract 196).
  • Emery, P., Fleischmann, R., Filipowicz-Sosnowska, A., Schechtman, J., Szczepanski, L., Kavanaugh, A., Racewicz, A.J., Van Vollenhoven, R.F., Li, N.F., Agarwal, S., Hessey, E.W., Shaw, T.M. & for the DANCER Study Group (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis & Rheumatism, 54, 13901400.
  • Fabbri, A., Gozzetti, A., Lazzi, S., Lenoci, M., D’Amuri, A., Leoncini, L. & Lauria, F. (2006) Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia. Clinical Lymphoma & Myeloma, 6, 496499.
  • Fakhouri, F., Vernant, J.P., Veyradier, A., Wolf, M., Kaplanski, G., Binaut, R., Rieger, M., Scheiflinger, F., Poullin, P., Deroure, B., Delarue, R., Lesavre, P., Vanhille, P., Hermine, O., Remuzzi, G. & Grünfeld, J.P. (2005) Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood, 106, 19321937.
  • Field, J.J., Fenske, T.S. & Blinder, M.A. (2007) Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy. Haemophilia, 13, 4650.
  • Fischer, K.G., Deschler, B. & Lübbert, M. (2003) Acquired high-titer factor VIII inhibitor: fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmaphereses. Blood, 101, 37533754.
  • Frederiksen, H. & Schmidt, K. (1999) The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood, 94, 909913.
  • Freim Wahl, S.G., Folvik, M.R. & Torp, S.H. (2007) Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: case report and review of the literature. Clinical Neuropathology, 26, 6873.
  • Galbusera, M., Bresin, E., Noris, M., Gastoldi, S., Belotti, D., Capoferri, C., Daina, E., Perseghin, P., Scheiflinger, F., Fakhouri, F., Grünfeld, J.P., Pogliani, E. & Remuzzi, G. (2005) Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. Blood, 106, 925928.
  • Garcia-Chavez, J., Majluf-Cruz, A., Montiel-Cervantes, L., Esparza, M.G. & Vela-Ojeda, J. (2007) Rituximab therapy for chonic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis. Annals of Hematology, 86, 871877.
  • Gehrs, B.C. & Friedberg, R.C. (2002) Autoimmune hemolytic anemia. American Journal of Hematology, 69, 258271.
  • George, J.N. (2000) How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood, 96, 12231229.
  • George, J.N., El-Harake, M.A. & Raskob, G.E. (1994) Chronic idiopathic thrombocytopenic purpura. New England Journal of Medicine, 331, 12071211.
  • George, J.N., Sadler, J.E. & Lämmle, B. (2002) Platelets: thrombotic thrombocytopenic purpura. Hematology/the Education Program of the American Society of Hematology, 315334.
  • Gertz, M.A. (2006) Cold agglutinin disease. Haematologica, 91, 439441.
  • Giagounidis, A.A., Anhuf, J., Schneider, P., Germing, U., Sohngen, D., Quabeck, K. & Aul, C. (2002) Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. European Journal of Haematology, 69, 95100.
  • Gianfaldoni, G., Antonioli, E., Mannelli, F., Vannucchi, A.M. & Bosi, A. (2005) Chronic relapsing thrombotic thrombocytopenic purpura successfully treated with rituximab: case report. Journal of Chemotherapy (Florence, Italy), 7, 449451.
  • Giulino, L.B., Bussel, J.B. & Neufeld, E.J. (2007) Treatment with rituximab in benign and malignant hematologic disorders in children. Journal of Pediatrics, 150, 338344.
  • Godeau, B., Fain, O., Porcher, R., Lefrere, F., Fenaux, P., Cheze, S., Vekhoff, A., Chauveheid, M.-P., Stirnemann, J., Galicier, L., Bourgeois, E., Haiat, S., Varet, B., Leporrier, M., Papo, T., Michel, M. & Bierling, P. (2006) Rituximab is an alternative to splenectomy in adults with chronic immune thrombocytopenic purpura: results of a multicenter prospective Phase 2 study. ASH Annual Meeting Abstracts. Blood, 108, 145a (Abstract 478).
  • Goldberg, S.L., Pecora, A.L., Alter, R.S., Kroll, M.S., Rowley, S.D., Waintraub, S.E., Imrit, K. & Preti, R.A. (2002) Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood, 99, 14861488.
  • Green, D. & Lechner, K. (1981) A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thrombosis and Haemostasis, 45, 200203.
  • Gupta, N., Kavuru, S., Patel, D., Janson, D., Driscoll, N., Ahmed, S. & Rai, K.R. (2002) Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia, 16, 20922095.
  • Gutterman, L.A., Kloster, B. & Tsai, H.M. (2002) Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells, Molecules & Diseases, 28, 385391.
  • Hainsworth, J.D., Litchy, S., Shaffer, D.W., Lackey, V.L., Grimaldi, M. & Greco, F.A. (2005) Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma – a randomized Phase II trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology, 23, 10881095.
  • Hay, C.R., Brown, S., Collins, P.W., Keeling, D.M. & Liesner, R. (2006) The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. British Journal of Haematology, 133, 591605.
  • Heidel, F., Lipka, D.B., Von Auer, C., Huber, C., Scharrer, I. & Hess, G. (2007) Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia. Thrombosis and Haemostasis, 97, 228233.
  • Herbei, L. & Venugopal, P. (2006) Recurrent thrombotic thrombocytopenic purpura treated repeatedly and successfully with the monoclonal antibody rituximab. Clinical Advances in Hematology & Oncology, 4, 215217.
  • Herman, C., Boggio, L. & Green, D. (2005) Factor VIII inhibitor associated with peginterferon. Haemophilia, 11, 408410.
  • Holme, P.A., Brosstad, F. & Tjønnfjord, G.E. (2005) Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies. Haemophilia, 11, 510515.
  • Hull, M.J. & Eichbaum, Q.G. (2006) Efficacy of rituximab and concurrent plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Clinical Advances in Hematology & Oncology, 4, 210214.
  • Joshi, A.V., Stephens, J.M., Munro, V., Mathew, P. & Botteman, M.F. (2006) Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors. Current Medical Research and Opinion, 22, 2331.
  • Jy, W., Gagliano-DeCesare, T., Kett, D.H., Horstman, L.L., Jimenez, J.J., Ruiz-Dayao, Z., Santos, E.S. & Ahn, Y.S. (2003) Life-threatening bleeding from refractory acquired FVIII inhibitor successfully treated with rituximab. Acta Haematologica, 109, 206208.
  • Kain, S., Copeland, T.S. & Leahy, M.F. (2002) Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab). British Journal of Haematology, 119, 578.
  • Kameda, T., Dobashi, H., Kittaka, K., Susaki, K., Yamaoka, G., Arai, K., Tokuda, M. & Ishida, T. (2007) Two cases of refractory thrombotic thrombocytopenic purpura associated with collagen vascular disease were significantly improved by rituximab treatment. Clinical Rheumatology, 26, 21592162.
  • Kang, C.M., Lee, J.G., Kim, K.S., Choi, J.S., Lee, W.J., Kim, B.R., Ko, Y.W., Han, J.S. & Min, Y.H. (2007) Long-term follow-up of laparoscopic splenectomy in patients with immune thrombocytopenic purpura. Journal of Korean Medical Science, 22, 420424.
  • Kappers-Klunne, M.C., Wijermans, P., Fijnheer, R., Croockewit, A.J., Van Der Holt, B., De Wolf, J.T., Löwenberg, B. & Brand, A. (2005) Splenectomy for the treatment of thrombotic thrombocytopenic purpura. British Journal of Haematology, 130, 768776.
  • Kimby, E. (2005) Tolerability and safety of rituximab (MabThera). Cancer Treatment Reviews, 31, 456473.
  • King, K.E. & Ness, P.M. (2005) Treatment of autoimmune hemolytic anemia. Seminars in Hematology, 42, 131136.
  • Kosugi, S., Matsumoto, M., Ohtani, Y., Take, H., Ishizashi, H., Fujimura, Y. & Kuyama, J. (2005) Rituximab provided long-term remission in a patient with refractory relapsing thrombotic thrombocytopenic purpura. International Journal of Hematology, 81, 433436.
  • Koulova, L., Alexandrescu, D., Dutcher, J.P., O’Boyle, K.P., Eapen, S. & Wiernik, P.H. (2005) Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases. American Journal of Hematology, 78, 4954.
  • Kranick, S.M., Mowry, E.M. & Rosenfeld, M.R. (2007) Progressive multifocal leukoencephalopathy after rituximab in a case of non-Hodgkin lymphoma. Neurology, 69, 704706.
  • Kumar, S., Diehn, F.E., Gertz, M.A. & Tefferi, A. (2002) Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses. Annals of Hematology, 81, 312319.
  • Lämmle, B., Kremer Hovinga, J.A. & Alberio, L. (2005) Thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 3, 16631675.
  • Lemieux, B., Bouafia, F., Thieblemont, C., Hequet, O., Arnaud, P., Tartas, S., Traulle, C., Salles, G. & Coiffier, B. (2004) Second treatment with rituximab in B-cell non-Hodgkin’s lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon Sud. Hematology Journal, 5, 467471.
  • Looney, R.J. (2002) Treating human autoimmune disease by depleting B cells. Annals of Rheumatic Diseases, 61, 863866.
  • Lottenberg, R., Kentro, T.B. & Kitchens, C.S. (1987) Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Archives of Internal Medicine, 147, 10771081.
  • Ma, A.D. & Carrizosa, D. (2006) Acquired factor VIII inhibitors: pathophysiology and treatment. Hematology/the Education Program of the American Society of Hematology, 432437.
  • Maillard, H., Launay, D., Hachulla, E., Goudemand, J., Lambert, M., Morell-Dubois, S., Queyrel, V. & Hatron, P.Y. (2006) Rituximab in postpartum-related acquired hemophilia. American Journal of Medicine, 119, 8688.
  • Marietta, M., Pozzi, S., Luppi, M., Bertesi, M., Cappi, C., Morselli, M. & Torelli, G. (2003) Acquired haemophilia in HIV negative, HHV-8 positive multicentric Castleman’s disease: a case report. European Journal of Haematology, 70, 181182.
  • Martin, F. & Chan, A.C. (2004) Pathogenic roles of B cells in human autoimmunity; insights from the clinic. Immunity, 20, 517527.
  • Martin, M.G., Whitlatch, N.L., Shah, B. & Arepally, G.M. (2007) Thrombotic thrombocytopenic purpura induced by trimethoprim-sulfamethoxazole in a Jehovah’s Witness. American Journal of Hematology, 82, 679881.
  • Matzdorff, A. & Arnold, G. (2007) Treatment of chronic immune thrombocytopenic purpura: the patients’ perspective. European Journal of Haematology, 78, 381388.
  • Millward, P.M., Bandarenko, N., Chang, P.P., Stagg, K.F., Afenyi-Annan, A., Hay, S.N. & Brecher, M.E. (2005) Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab. Transfusion, 45, 14811486.
  • Moake, J.L. (2002) Thrombotic microangiopathies. New England Journal of Medicine, 22, 589600.
  • Nakhoul, I.N., Kozuch, P. & Varma, M. (2006) Management of adult idiopathic thrombocytopenic purpura. Clinical Advances in Hematology & Oncology, 4, 136144.
  • Narat, S., Gandla, J., Hoffbrand, A.V., Hughes, R.G. & Mehta, A.B. (2005) Rituximab in the treatment of refractory autoimmune cytopenias in adults. Haematologica, 90, 12731274.
  • Neylon, A.J., Saunders, P.W., Howard, M.R., Proctor, S.J. & Taylor, P.R. (2003) Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. British Journal of Haematology, 122, 966974.
  • Niewold, T.B., Alpert, D., Scanzello, C.R. & Paget, S.A. (2006) Rituximab treatment of thrombotic thrombocytopenic purpura in the setting of connective tissue disease. Journal of Rheumatology, 33, 11941196.
  • O’Brien, S.H., Ritchey, A.K. & Smith, K.J. (2007) A cost–utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP). Pediatric Blood and Cancer, 48, 173180.
  • Van Oers, M.H., Klasa, R., Marcus, R.E., Wolf, M., Kimby, E., Gascoyne, R.D., Jack, A., Van’t Veer, M., Vranovsky, A., Holte, H., Van Glabbeke, M., Teodorovic, I., Rozewicz, C. & Hagenbeek, A. (2006) Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin’s lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood, 108, 32953301.
  • Oliveira, B., Arkfeld, D.G., Weitz, I.C., Shinada, S. & Ehresmann, G. (2007) Successful rituximab therapy of acquired factor VIII inhibitor in a patient with rheumatoid arthritis. Journal of Clinical Rheumatology, 13, 8991.
  • Onitilo, A.A., Skorupa, A., Lal, A., Ronish, E., Mercier, R.J., Islam, R. & Lazarchick, J. (2006) Rituximab in the treatment of acquired factor VIII inhibitors. Thrombosis & Haemostasis, 96, 8487.
  • Outschoorn, U.M. & Ferber, A. (2006) Outcomes in the treatment of thrombotic thrombocytopenic purpura with splenectomy: a retrospective cohort study. American Journal of Hematology, 81, 895900.
  • Ozdogu, H., Boga, C., Kizilkilic, E., Yeral, M., Kozanoglu, I. & Karatas, M. (2007) A dramatic response to rituximab in a patient with resistant thrombotic thrombocytopenic purpura (TTP) who developed acute stroke. Journal of Thrombosis and Thrombolysis, 23, 147150.
  • Parodi, E., Nobili, B., Perrotta, S., Rosaria Matarese, S.M., Russo, G., Licciardello, M., Zecca, M., Locatelli, F., Cesaro, S., Bisogno, G., Giordano, P., De Mattia, D. & Ramenghia, U. (2006) Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment. International Journal of Hematology, 84, 4853.
  • Patino, W. & Sarode, R. (2007) Successful repeat therapy with rituximab for relapsed thrombotic thrombocytopenic purpura. Journal of Clinical Apheresis, 22, 1720.
  • Penalver, F.J., Jimenez-Yuste, V., Almagro, M., Alvarez-Larran, A., Rodriguez, L., Casado, M., Gallur, L., Giraldo, P., Hernández, R., Menor, D., Rodríguez, M.J., Caballero, D., González, R., Mayans, J., Millán, I., Cabrera, J.R. & for the Multi-institutional Retrospective Spanish Study Group on the Use of Rituximab in Refractory ITP (2006) Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Annals of Hematology, 85, 400406.
  • Pérez-Calvo, J.I., Ruiz-Ruiz, F., Amores, B. & Torralba, M.A. (2005) Long-term cost-efficacy of rituximab in immune thrombocytopenic purpura. QJM: Monthly Journal of the Association of Physicians, 98, 839840.
  • Petz, L.D. (2001) Treatment of autoimmune hemolytic anemias. Current Opinion in Hematology, 8, 411416.
  • Pulik, M., Genet, P., Lionnet, F. & Touahri, T. (2002) Treatment of primary chronic cold agglutinin disease with rituximab: maintenance therapy may improve the results. British Journal of Haematology, 117, 998999.
  • Quartier, P., Brethon, B., Philippet, P., Landman-Parker, J., Le Deist, F. & Fischer, A. (2001) Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet, 358, 15111513.
  • Rao, A., Kelly, M., Musselman, M., Ramadas, J., Wilson, D., Grossman, W. & Shenoy, S. (2007) Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatric Blood & Cancer, [Epub ahead of print] doi: 10.1002/pbc.21264.
  • Rastetter, W., Molina, A. & White, C.A. (2004) Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annual Review of Medicine, 55, 477503.
  • Reddy, P.S., Deauna-Limayo, D., Cook, J.D., Ganguly, S.S., Blecke, C., Bodensteiner, D.C., Skikne, B.S. & Sahud, M.A. (2005) Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura. Annals of Hematology, 84, 232235.
  • Reff, M.E., Carner, K., Chambers, K.S., Chinn, P.C., Leonard, J.E., Raab, R., Newman, R.A., Hanna, N. & Anderson, D.R. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood, 83, 435445.
  • Rizvi, M.A., Vesely, S.K., George, J.N., Chandler, L., Duvall, D., Smith, J.W. & Gilcher, R.O. (2000) Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome. Transfusion, 40, 896901.
  • Rose, N.R. & Mackay, I.R. (1998) Autoimmune Diseases, 3rd edn Academic Press Inc., San Diego, CA.
  • Sadler, J.E., Moake, J.L., Miyata, T. & George, J.N. (2004) Recent advances in thrombotic thrombocytopenic purpura. Hematology/the Education Program of the American Society of Hematology, 407423.
  • Saleh, M.N., Gutheil, J., Moore, M., Bunch, P.W., Butler, J., Kunkel, L., Grillo-López, A.J. & LoBuglio, A.F. (2000) A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Seminars in Oncology, 27(Suppl. 12), 99103.
  • Sallah, S. & Aledort, L. (2005) Treatment of patients with acquired inhibitors. Journal of Thrombosis and Haemostasis, 3, 595597.
  • Sallah, S., Husain, A., Wan, J.Y. & Nguyen, N.P. (2004) Rituximab in patients with refractory thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2, 834836.
  • Santoro, C., Rago, A., Biondo, F., De Propris, M.S., De Vellis, A., Guarini, A., Pignoloni, P. & Mazzucconi, M.G. (2007) Efficacy of rituximab treatment in postpartum acquired haemophilia A. Haemophilia, 14, 147149.
  • Scheinberg, M., Hamerschlak, N., Kutner, J.M., Ribeiro, A.A., Ferreira, E., Goldenberg, J., Kiss, M.H. & Chahade, W.H. (2006) Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002–2004). Clinical and Experimental Rheumatology, 24, 6569.
  • Schleinitz, N., Ebbo, M., Mazodier, K., Poullin, P., Bernit, E., Veit, V., Veyradier, A., Fakhouri, F., Kaplanski, G. & Harle, J.R. (2007) Rituximab as preventive therapy of a clinical relapse in TTP with ADAMTS13 inhibitor. American Journal of Hematology, 82, 417418.
  • Schöllkopf, C., Kjeldsen, L., Bjerrum, O.W., Mourits-Andersen, H.T., Nielsen, J.L., Christensen, B.E., Jensen, B.A., Pedersen, B.B., Taaning, E.B., Klausen, T.W. & Birgens, H. (2006) Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leukemia & Lymphoma, 47, 253260.
  • Schweizer, C., Reu, F.J., Ho, A.D. & Hensel, M. (2007) Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab. Annals of Hematology, 86, 711717.
  • Scully, M., Cohen, H., Cavenagh, J., Benjamin, S., Starke, R., Killick, S., Mackie, I. & Machin, S.J. (2007) Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. British Journal of Haematology, 136, 451461.
  • Semple, J.W. (2007) Rituximab disciplines T cells, spares platelets. Blood, 110, 27842785.
  • Semple, J.W. & Freedman, J. (2005) Autoimmune pathogenesis and autoimmune hemolytic anemia. Seminars in Hematology, 42, 122130.
  • Shanafelt, T.D., Madueme, H.L., Wolf, R.C. & Tefferi, A. (2003) Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clinic Proceedings, 78, 13401346.
  • Silverman, G.J. & Weisman, S. (2003) Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis and Rheumatism, 48, 14841492.
  • Sokol, R.J., Booker, D.J. & Stamps, R. (1992) The pathology of autoimmune haemolytic anaemia. Journal of Clinical Pathology, 45, 10471052.
  • Stasi, R., Pagano, A., Stipa, E. & Amadori, S. (2001) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood, 98, 952957.
  • Stasi, R., Stipa, E., Forte, V., Meo, P. & Amadori, S. (2002) Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood, 99, 38723873.
  • Stasi, R., Brunetti, M., Stipa, E. & Amadori, S. (2004) Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood, 103, 44244428.
  • Stasi, R., Del Poeta, G., Stipa, E., Evangelista, M.L., Trawinska, M.M., Cooper, N. & Amadori, S. (2007) Response to B-cell depleting therapy with rituximab reverts the abnormalities of T cell subsets in patients with idiopathic thrombocytopenic purpura. Blood, 110, 29242930.
  • Stein, G.Y., Zeidman, A., Fradin, Z., Varon, M., Cohen, A. & Mittelman, M. (2004) Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamide. International Journal of Hematology, 80, 9496.
  • Steurer, M., Clausen, J., Gotwald, T., Gunsilius, E., Stockhammer, G., Gastl, G. & Nachbaur, D. (2003) Progressive multifocal leukoencephalopathy after allogeneic stem cell transplantation and posttransplantation rituximab. Transplantation, 76, 435436.
  • Sutor, A.H., Harms, A. & Kaufmehl, K. (2001) Acute immune thrombocytopenia (ITP) in childhood: retrospective and prospective survey in Germany. Seminars in Thrombosis and Hemostasis, 27, 253267.
  • Taube, T., Schmid, H., Reinhard, H., Von Stackelberg, A. & Overberg, U.S. (2005) Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood. Haematologica, 90, 281283.
  • Taylor, R.P. & Lindorfer, M.A. (2007) Drug insight: the mechanism of action of rituximab in autoimmune disease – the immune complex decoy hypothesis. Nature Clinical Practice. Rheumatology, 3, 8695.
  • Trapè, G., Fianchi, L., Lai, M., Laurenti, L., Piscitelli, R., Leone, G. & Pagano, L. (2003) Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders. Haematologica, 88, 223225.
  • Tsai, H.M. (2003) Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. Journal of the American Society of Nephrology, 14, 10721081.
  • Veyradier, A. & Meyer, D. (2005) Thrombotic thrombocytopenic purpura and its diagnosis. Journal of Thrombosis and Haemostasis, 3, 24202427.
  • Wang, J., Wiley, J.M., Luddy, R., Greenberg, J., Feuerstein, M.A. & Bussel, J.B. (2005) Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. Journal of Pediatrics, 146, 217221.
  • Wang, T., Xu, M., Ji, L. & Yang, R. (2006) Splenectomy for chronic idiopathic thrombocytopenic purpura in children: a single center study in China. Acta Haematologia, 115, 3945.
  • Wiestner, A., Cho, H.J., Asch, A.S., Michelis, M.A., Zeller, J.A., Peerschke, E.I., Weksler, B.B. & Schechter, G.P. (2002) Rituximab in the treatment of acquired factor VIII inhibitors. Blood, 100, 34263428.
  • Yomtovian, R., Niklinski, W., Silver, B., Sarode, R. & Tsai, H.M. (2004) Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. British Journal of Haematology, 124, 787795.
  • Zaja, F., Vianelli, N., Sperotto, A., De Vita, S., Iacona, I., Zaccaria, A., Masolini, P., Tomadini, V., Tani, M., Molinari, A.L., Baccarani, M. & Fanin, R. (2003a) B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica, 88, 538546.
  • Zaja, F., Vianelli, N., Sperotto, A., Patriarca, F., Tani, M., Marin, L., Tiribelli, M., Candoni, A., Baccarani, M. & Fanin, R. (2003b) Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leukemia & Lymphoma, 44, 19511955.
  • Zaja, F., Vianelli, N., Battista, M., Sperotto, A., Patriarca, F., Tomadini, V., Filì, C., Tani, M., Baccarani, M. & Fanin, R. (2006) Earlier administration of rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia. Experimental Hematology, 34, 571572.
  • Zecca, M., Nobili, B., Ramenghi, U., Perrotta, S., Amendola, G., Rosito, P., Jankovic, M., Pierani, P., De Stefano, P., Bonora, M.R. & Locatelli, F. (2003) Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood, 101, 38573861.
  • Zeller, B., Rajantie, J., Hedlund-Treutiger, I., Tedgard, U., Wesenberg, F., Jonsson, O.G. & Henter, J.I. (2005) Childhood idiopathic thrombocytopenic purpura in the Nordic countries: epidemiology and predictors of chronic disease. Acta Paediatrica, 94, 178184.
  • Zheng, X., Pallera, A.M., Goodnough, L.T., Sadler, J.E. & Blinder, M.A. (2003) Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Annals of Internal Medicine, 138, 105108.